The integrin binding peptide, atn-161, as a novel therapy for SARS-CoV-2 infection
Many efforts to design and screen therapeutics for the current severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry by disrupting ACE2 binding with the SARS-CoV-2 spike protein. This work focuses on the potential to inhibit SARS-CoV-2 e...
- Autores:
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/14657
- Acceso en línea:
- https://doi.org/10.1016/j.jacbts.2020.10.003
http://hdl.handle.net/20.500.12010/14657
- Palabra clave:
- COVID-19
SARS-CoV-2
ACE2
Alpha5beta1 integrin
ATN-161
Therapeutic
Host-cell entry
Viral spike protein
Receptor binding domain
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Abierto (Texto Completo)
| id |
UTADEO2_43ec24fa03726802d3dd66c039808394 |
|---|---|
| oai_identifier_str |
oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/14657 |
| network_acronym_str |
UTADEO2 |
| network_name_str |
Expeditio: repositorio UTadeo |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
The integrin binding peptide, atn-161, as a novel therapy for SARS-CoV-2 infection |
| title |
The integrin binding peptide, atn-161, as a novel therapy for SARS-CoV-2 infection |
| spellingShingle |
The integrin binding peptide, atn-161, as a novel therapy for SARS-CoV-2 infection COVID-19 SARS-CoV-2 ACE2 Alpha5beta1 integrin ATN-161 Therapeutic Host-cell entry Viral spike protein Receptor binding domain Síndrome respiratorio agudo grave COVID-19 SARS-CoV-2 Coronavirus |
| title_short |
The integrin binding peptide, atn-161, as a novel therapy for SARS-CoV-2 infection |
| title_full |
The integrin binding peptide, atn-161, as a novel therapy for SARS-CoV-2 infection |
| title_fullStr |
The integrin binding peptide, atn-161, as a novel therapy for SARS-CoV-2 infection |
| title_full_unstemmed |
The integrin binding peptide, atn-161, as a novel therapy for SARS-CoV-2 infection |
| title_sort |
The integrin binding peptide, atn-161, as a novel therapy for SARS-CoV-2 infection |
| dc.subject.spa.fl_str_mv |
COVID-19 SARS-CoV-2 ACE2 Alpha5beta1 integrin ATN-161 Therapeutic Host-cell entry Viral spike protein Receptor binding domain |
| topic |
COVID-19 SARS-CoV-2 ACE2 Alpha5beta1 integrin ATN-161 Therapeutic Host-cell entry Viral spike protein Receptor binding domain Síndrome respiratorio agudo grave COVID-19 SARS-CoV-2 Coronavirus |
| dc.subject.lemb.spa.fl_str_mv |
Síndrome respiratorio agudo grave COVID-19 SARS-CoV-2 Coronavirus |
| description |
Many efforts to design and screen therapeutics for the current severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry by disrupting ACE2 binding with the SARS-CoV-2 spike protein. This work focuses on the potential to inhibit SARS-CoV-2 entry through a hypothesized α5β1 integrin-based mechanism, and indicates that inhibiting the spike protein interaction with α5β1 integrin (+/- ACE2), and the interaction between α5β1 integrin and ACE2 using a novel molecule ATN-161 represents a promising approach to treat COVID-19. |
| publishDate |
2020 |
| dc.date.accessioned.none.fl_str_mv |
2020-10-21T17:00:36Z |
| dc.date.available.none.fl_str_mv |
2020-10-21T17:00:36Z |
| dc.date.created.none.fl_str_mv |
2020 |
| dc.type.local.spa.fl_str_mv |
Artículo |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| format |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.identifier.issn.spa.fl_str_mv |
2452-302X |
| dc.identifier.other.spa.fl_str_mv |
https://doi.org/10.1016/j.jacbts.2020.10.003 |
| dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/20.500.12010/14657 |
| dc.identifier.doi.spa.fl_str_mv |
https://doi.org/10.1016/j.jacbts.2020.10.003 |
| identifier_str_mv |
2452-302X |
| url |
https://doi.org/10.1016/j.jacbts.2020.10.003 http://hdl.handle.net/20.500.12010/14657 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| dc.rights.local.spa.fl_str_mv |
Abierto (Texto Completo) |
| rights_invalid_str_mv |
Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 |
| dc.format.extent.spa.fl_str_mv |
24 páginas |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
JACC: Basic to Translational Science |
| dc.source.spa.fl_str_mv |
reponame:Expeditio Repositorio Institucional UJTL instname:Universidad de Bogotá Jorge Tadeo Lozano |
| instname_str |
Universidad de Bogotá Jorge Tadeo Lozano |
| institution |
Universidad de Bogotá Jorge Tadeo Lozano |
| reponame_str |
Expeditio Repositorio Institucional UJTL |
| collection |
Expeditio Repositorio Institucional UJTL |
| bitstream.url.fl_str_mv |
https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/14657/2/license.txt https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/14657/3/The-Integrin-Binding-Peptide--ATN-161--as-a-Novel_2020_JACC--Basic-to-Transl.pdf.jpg |
| bitstream.checksum.fl_str_mv |
abceeb1c943c50d3343516f9dbfc110f 559b9870dc60492f7fd5ce74f6de9a20 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional - Universidad Jorge Tadeo Lozano |
| repository.mail.fl_str_mv |
expeditio@utadeo.edu.co |
| _version_ |
1818152671929958400 |
| spelling |
2020-10-21T17:00:36Z2020-10-21T17:00:36Z20202452-302Xhttps://doi.org/10.1016/j.jacbts.2020.10.003http://hdl.handle.net/20.500.12010/14657https://doi.org/10.1016/j.jacbts.2020.10.003Many efforts to design and screen therapeutics for the current severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic have focused on inhibiting viral host cell entry by disrupting ACE2 binding with the SARS-CoV-2 spike protein. This work focuses on the potential to inhibit SARS-CoV-2 entry through a hypothesized α5β1 integrin-based mechanism, and indicates that inhibiting the spike protein interaction with α5β1 integrin (+/- ACE2), and the interaction between α5β1 integrin and ACE2 using a novel molecule ATN-161 represents a promising approach to treat COVID-19.24 páginasapplication/pdfengJACC: Basic to Translational Sciencereponame:Expeditio Repositorio Institucional UJTLinstname:Universidad de Bogotá Jorge Tadeo LozanoCOVID-19SARS-CoV-2ACE2Alpha5beta1 integrinATN-161TherapeuticHost-cell entryViral spike proteinReceptor binding domainSíndrome respiratorio agudo graveCOVID-19SARS-CoV-2CoronavirusThe integrin binding peptide, atn-161, as a novel therapy for SARS-CoV-2 infectionArtículohttp://purl.org/coar/resource_type/c_2df8fbb1Abierto (Texto Completo)http://purl.org/coar/access_right/c_abf2Beddingfield, Brandon J.Iwanaga, NaokiChapagain, Prem P.Zheng, WenshuRoy, Chad J.Hu, Tony Y.Kolls, Jay K.Bix, Gregory J.LICENSElicense.txtlicense.txttext/plain; charset=utf-82938https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/14657/2/license.txtabceeb1c943c50d3343516f9dbfc110fMD52open accessTHUMBNAILThe-Integrin-Binding-Peptide--ATN-161--as-a-Novel_2020_JACC--Basic-to-Transl.pdf.jpgThe-Integrin-Binding-Peptide--ATN-161--as-a-Novel_2020_JACC--Basic-to-Transl.pdf.jpgIM Thumbnailimage/jpeg11923https://expeditiorepositorio.utadeo.edu.co/bitstream/20.500.12010/14657/3/The-Integrin-Binding-Peptide--ATN-161--as-a-Novel_2020_JACC--Basic-to-Transl.pdf.jpg559b9870dc60492f7fd5ce74f6de9a20MD53open access20.500.12010/14657oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/146572021-03-12 18:16:52.507metadata only accessRepositorio Institucional - Universidad Jorge Tadeo Lozanoexpeditio@utadeo.edu.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 |